Biomarkers and Choroidal Neovascularization
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorInstitut National de la Santé Et de la Recherche Médicale, France
About this trial
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration
Patients without intravitreal injection or last intravitreal injection > 3 months
Informed signed consent
Patients without choroidal neovascularization
Disqualifiers
Myocardial infarction < 12 months
Chronic renal failure
Inflammatory disease
Infectious disease :HIV, viral hepatitis, tuberculosis
Trial population
Group 1 : patients with type 1 choroidal neovascularization Group 2: patients without choroidal neovascularization before ocular surgery
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Blood and aqueous humor biomarker of treatment response
Other interventionBlood analyses and aqueous humor analysis
Treatment groups
250 Participants
are divided into 2 treatment groupsGroup A: Group 11 intervention
Group B: Group 21 intervention
Trial outcomes
Primary outcomes
1
biomarker analysis in blood and aqueous humor of patients with neovascularization and controls
Biomarker concentrations (pg/ml) will be evaluated with ELISA (Enzyme Linked ImmunoSorbent Assay).
Time frame
24 months2
biomarker analysis in blood and aqueous humor of patients with neovascularization and controls
Biomarker concentrations (pg/ml) will be evaluated with Mulitplex Biorad.
Time frame
24 monthsSecondary outcomes
1
biomarkers and treatment response
Correlation between biomarker level and the response to anti-VEGF treatment
Time frame
24 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov